Together, these findings have suggested that the microenvironments of prostate tumors may be different from those of other solid tumors and that additional immune regulatory cells, cytokines, or other metabolic factors such as hypoxia may affect the function of tumor-infiltrating CD8+ T cells and the response of prostate tumors to immune therapies [11]. This evidence concerns the gene CD8A and neoplasm.